Contact A Rep |

INDICATION

CABOMETYX^® (cabozantinib), in combination with nivolumab, is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

Please see important safety information below.

Based on IQVIA claims as of December 2023. Subject to change without notice.¹

LEARN MORE

In the primary analysis, CABOMETYX + OPDIVO^® (nivolumab) demonstrated superior efficacy vs sunitinib in 1L aRCC across PFS, OS, and ORR²

Progression-free survival (PFS), primary endpoint, assessed by BICR

PFS doubled in the primary analysis²

•

mPFS in the primary analysis (median follow-up time of 18.1 months; range: 10.6-30.6 months): 16.6 months for CABOMETYX + OPDIVO (95% CI: 12.5-24.9; n=323) vs 8.3 months for sunitinib (95% CI: 7.0-9.7; n=328); HR=0.51 (95% CI: 0.41-0.64); P<0.0001^2,3

Primary endpoint

PFS 4-year minimum follow-up analysis⁴

Median follow-up time of 55.6 months; range: 48.1-68.1 months⁴

No formal statistical testing was conducted at the time of the updated analysis.

Select Important Safety Information

The full Prescribing Information for CABOMETYX includes Warnings and Precautions for: hemorrhage, perforations and fistulas, thrombotic events, hypertension and hypertensive crises, diarrhea, palmar-plantar erythrodysesthesia (PPE), hepatotoxicity, adrenal insufficiency, proteinuria, osteonecrosis of the jaw, impaired wound healing, reversible posterior leukoencephalopathy syndrome, thyroid dysfunction, hypocalcemia, and embryo-fetal toxicity.

See additional important safety information below.

Overall survival (OS), secondary endpoint

Superior median OS in the primary analysis²

•

Median OS in the primary analysis (median follow-up time of 18.1 months; range: 10.6-30.6 months): 40% reduction in the risk of death, HR=0.60 (98.89% CI: 0.40-0.89; P<0.001); median OS was not reached in either treatment arm^2,3

•

Pre-planned final analysis of OS (median follow-up: 32.9 months; range: 25.4-45.4 months): Median OS was 37.7 months for CABOMETYX + OPDIVO (95% Cl: 35.5-NR; n=323) compared with 34.3 months for sunitinib (95% Cl: 29.0-NR; n=328); HR=0.70 (95% Cl: 0.55-0.90)^2,5,6

Secondary endpoint

OS 4-year minimum follow-up analysis⁴

Median follow-up time of 55.6 months; range: 48.1-68.1 months⁴

No formal statistical testing was conducted at the time of the updated analysis.

Objective response rate (ORR), secondary endpoint, assessed by BICR

ORR doubled in the primary analysis²

•

ORR results in the primary analysis (median follow-up time of 18.1 months; range: 10.6-30.6 months): 55.7% with CABOMETYX + OPDIVO (95% CI: 50.1-61.2; n=323; P<0.0001) vs 27.1% for sunitinib (95% CI: 22.4-32.3; n=328; P<0.0001)^2,3

Study Design

CheckMate-9ER was a randomized (1:1), open-label, Phase 3 trial vs sunitinib in 651 patients with previously untreated aRCC with a clear-cell component. The trial evaluated CABOMETYX 40 mg (starting dose) PO once daily in combination with OPDIVO. The primary endpoint was PFS, and secondary endpoints included OS, ORR, and safety.^2,3,7

DISCOVER THE BALANCE OF DATA

1L=first-line; aRCC=advanced renal cell carcinoma; BICR=blinded independent central review; CI=confidence interval; HR=hazard ratio; IO=immunotherapy; IV=intravenous; NR=not reached; ORR=objective response rate; OS=overall survival; PFS=progression-free survival; PO=taken orally; TKI=tyrosine kinase inhibitor.

INDICATION

CABOMETYX^® (cabozantinib), in combination with nivolumab, is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hemorrhage: Severe and fatal hemorrhages occurred with CABOMETYX. Discontinue CABOMETYX for Grade 3-4 hemorrhage and before surgery. Do not administer to patients who have a recent history of hemorrhage, including hemoptysis, hematemesis, or melena.

Perforations and Fistulas: Fistulas, including fatal cases, and gastrointestinal (GI) perforations, including fatal cases, occurred in CABOMETYX patients. Monitor for signs and symptoms and discontinue in patients with Grade 4 fistulas or GI perforation.

Thrombotic Events: CABOMETYX increased the risk of thrombotic events. Fatal thrombotic events have occurred. Discontinue CABOMETYX in patients who develop an acute myocardial infarction or serious arterial or venous thromboembolic events.

Hypertension and Hypertensive Crisis: CABOMETYX can cause hypertension including hypertensive crisis. Monitor blood pressure regularly during CABOMETYX treatment. Withhold CABOMETYX for hypertension that is not adequately controlled; when controlled, resume at a reduced dose. Permanently discontinue CABOMETYX for severe hypertension that cannot be controlled with anti-hypertensive therapy or for hypertensive crisis.

Diarrhea: Diarrhea may be severe. Monitor and manage patients using antidiarrheals as indicated. Withhold CABOMETYX until improvement to ≤ Grade 1, resume at a reduced dose.

Palmar-Plantar Erythrodysesthesia (PPE): Withhold CABOMETYX until PPE resolves or decreases to Grade 1 and resume at a reduced dose for intolerable Grade 2 PPE or Grade 3 PPE.

Hepatotoxicity: CABOMETYX in combination with nivolumab can cause hepatic toxicity with higher frequencies of Grades 3 and 4 ALT and AST elevations compared to CABOMETYX alone. Monitor liver enzymes before initiation of and periodically throughout treatment. Consider withholding CABOMETYX and/or nivolumab, initiating corticosteroid therapy, and/or permanently discontinuing the combination for severe or life-threatening hepatotoxicity.

Adrenal Insufficiency: CABOMETYX in combination with nivolumab can cause primary or secondary adrenal insufficiency. For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold CABOMETYX and/or nivolumab and resume CABOMETYX at a reduced dose depending on severity.

Proteinuria: Monitor urine protein regularly during CABOMETYX treatment. For Grade 2 or 3 proteinuria, withhold CABOMETYX until improvement to ≤ Grade 1 proteinuria; resume CABOMETYX at a reduced dose. Discontinue CABOMETYX in patients who develop nephrotic syndrome.

Osteonecrosis of the Jaw (ONJ): Perform an oral examination prior to CABOMETYX initiation and periodically during treatment. Advise patients regarding good oral hygiene practices. Withhold CABOMETYX for at least 3 weeks prior to scheduled dental surgery or invasive dental procedures. Withhold CABOMETYX for development of ONJ until complete resolution, resume at a reduced dose.

Impaired Wound Healing: Withhold CABOMETYX for at least 3 weeks prior to elective surgery. Do not administer for at least 2 weeks after major surgery and until adequate wound healing. The safety of resumption of CABOMETYX after resolution of wound healing complications has not been established.

Reversible Posterior Leukoencephalopathy Syndrome (RPLS): RPLS can occur with CABOMETYX. Evaluate for RPLS in patients presenting with seizures, headache, visual disturbances, confusion, or altered mental function. Discontinue CABOMETYX in patients who develop RPLS.

Thyroid Dysfunction: Thyroid dysfunction, primarily hypothyroidism, has been observed with CABOMETYX. Assess for signs of thyroid dysfunction prior to the initiation of CABOMETYX and monitor for signs and symptoms during treatment.

Hypocalcemia: Monitor blood calcium levels and replace calcium as necessary during treatment. Withhold and resume at reduced dose upon recovery or permanently discontinue CABOMETYX depending on severity.

Embryo-Fetal Toxicity: CABOMETYX can cause fetal harm. Advise pregnant women of the potential risk to fetus. Verify pregnancy status and advise use of effective contraception during treatment and for 4 months after last dose.

ADVERSE REACTIONS

The most common (≥20%) adverse reactions are:

CABOMETYX in combination with nivolumab: diarrhea, fatigue, hepatotoxicity, PPE, stomatitis, rash, hypertension, hypothyroidism, musculoskeletal pain, decreased appetite, nausea, dysgeusia, abdominal pain, cough, and upper respiratory tract infection.

DRUG INTERACTIONS

Strong CYP3A4 Inhibitors: If coadministration with strong CYP3A4 inhibitors cannot be avoided, reduce the CABOMETYX dosage. Avoid grapefruit or grapefruit juice.

Strong CYP3A4 Inducers: If coadministration with strong CYP3A4 inducers cannot be avoided, increase the CABOMETYX dosage. Avoid St. John’s wort.

USE IN SPECIFIC POPULATIONS

Lactation: Advise women not to breastfeed during CABOMETYX treatment and for 4 months after the final dose.

Hepatic Impairment: In patients with moderate hepatic impairment, reduce the CABOMETYX dosage. Avoid CABOMETYX in patients with severe hepatic impairment.

Please see full Prescribing Information for additional important safety information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

If you would like more information about CABOMETYX, please visit CABOMETYXhcp.com.

This email is intended for US healthcare professionals only.

This promotional email is brought to you by Exelixis.

References: 1. Data on file. IQVIA National Prescription Audit. December 2023. Exelixis, Inc. 2. CABOMETYX^® (cabozantinib) Prescribing Information. 3. Choueiri TK, Powles T, Burotto M, et al; CheckMateER Investigators. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829-841. 4. Bourlon MT, Escudier B, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for previously untreated advanced renal cell carcinoma: results from 55-month follow-up of the CheckMate 9ER trial. Presented at ASCO Genitourinary Cancers Symposium; January 27, 2024. 5. Motzer RJ, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomized, phase 3 trial. Lancet Oncol. 2022;23(7):888-898. 6. Powles T, Choueiri TK, Burotto M, et al. Final overall survival analysis and organ-specific target lesion assessments with 2-year follow-up in CheckMate 9ER: nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma. Poster presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium; February 17-19, 2022. 7. Motzer RJ, Choueiri TK, Powles T, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal cell carcinoma: outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER. Poster presented at Genitourinary Cancers Symposium; February 11-13, 2021.

Exelixis, Inc., 1851 Harbor Bay Parkway, Alameda, CA 94502

OPDIVO^® and the related logo are registered trademarks of Bristol-Myers Squibb Company.

03/24 CA-2523-2